Meeting
2021 Gastrointestinal Cancers Symposium
A phase Ib multicenter study of trifluridine/tipiracil (FTD/TPI) in combination with irinotecan (IRI) in patients with advanced recurrent or unresectable gastric and gastroesophageal adenocarcinoma (aGEC) after at least one line of treatment with a fluoropyrimidine and platinum containing regimen.
Authors
Farshid Dayyani
University of California Irvine, Division of Hematology/Oncology, Department of Medicine, Orange, CA
Farshid Dayyani , Kit Tam , Edward Kim , Parvin Keshtmand , Samuel Ejadi , Fa Chyi Lee , May Thet Cho
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session: Esophageal and Gastric Cancer
Track
Esophageal and Gastric Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT04074343
Citation
J Clin Oncol 39, 2021 (suppl 3; abstr TPS251)
DOI
10.1200/JCO.2021.39.3_suppl.TPS251
Abstract #
TPS251
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Real-world effectiveness of drugs newly approved in Japan on survival in patients with advanced gastric cancer.
First Author: Toru Kadono
Poster
2019 ASCO Annual Meeting
A phase II study of TAS-102 in combination with ramucirumab in advanced, refractory gastric or gastroesophageal junction (GEJ) adenocarcinoma.
First Author: Rutika Mehta
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Real-world comparison of treatment outcomes between advanced esophagogastric junction adenocarcinoma and gastric adenocarcinoma.
First Author: Toru Kadono
Poster
2023 ASCO Annual Meeting
VIC regimen (vemurafenib/irinotecan/cetuximab) versus bevacizumab plus chemotherapy as first-line treatment for BRAF V600E-mutated advanced colorectal cancer.
First Author: Yijiao Chen